ImmunoGen (NASDAQ:IMGN) : Wednesdays money flow data in ImmunoGen (NASDAQ:IMGN) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.97 million, whereas, $0.66 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.47, in favor of the bulls. The total money flow into the stock was $0.31 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0.08 million. The total value of block trades done on upticks was $0.08 million. ImmunoGen (NASDAQ:IMGN) fell $0.05 and traded at $3.13, down -1.57% for the day, over previous days close. On a weekly basis, the shares are 0% over the previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Executive Vice President) of Immunogen Inc, Lambert John had sold 3,889 shares worth of $31,968 in a transaction dated February 1, 2016. In this transaction, 3,889 shares were sold at $8.22 per share. Currently the company Insiders own 4.2% of ImmunoGen shares according to the proxy statements. Institutional Investors own 86.75% of ImmunoGen shares.
The company shares have dropped -77.72% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $19.43 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $4.86 and the 200 Day Moving Average price is recorded at $7.99. ImmunoGen (NASDAQ:IMGN): The stock opened at $3.25 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.28 for the day. The stock traded down to $3.05 during the day, due to lack of any buying support eventually closed down at $3.13 with a loss of -1.57% for the day. The stock had closed at $3.18 on the previous day. The total traded volume was 2,035,146 shares.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.